BRPI0806902A2 - MÉTODOS E COMPOSIÇÕES PARA MODULAÇÃO DAS VIAS DE METILAÇÃO DE DNA DIRECIONADA POR sIRNA E RNA - Google Patents

MÉTODOS E COMPOSIÇÕES PARA MODULAÇÃO DAS VIAS DE METILAÇÃO DE DNA DIRECIONADA POR sIRNA E RNA

Info

Publication number
BRPI0806902A2
BRPI0806902A2 BRPI0806902-6A2A BRPI0806902A BRPI0806902A2 BR PI0806902 A2 BRPI0806902 A2 BR PI0806902A2 BR PI0806902 A BRPI0806902 A BR PI0806902A BR PI0806902 A2 BRPI0806902 A2 BR PI0806902A2
Authority
BR
Brazil
Prior art keywords
methods
sirna
rna
compositions
modulation
Prior art date
Application number
BRPI0806902-6A2A
Other languages
English (en)
Inventor
Lionel Navarro
Olivier Voinnet
Original Assignee
Plant Bioscience Ltd
Lionel Navarro
Olivier Voinnet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plant Bioscience Ltd, Lionel Navarro, Olivier Voinnet filed Critical Plant Bioscience Ltd
Publication of BRPI0806902A2 publication Critical patent/BRPI0806902A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8281—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for bacterial resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BRPI0806902-6A2A 2007-01-19 2008-01-18 MÉTODOS E COMPOSIÇÕES PARA MODULAÇÃO DAS VIAS DE METILAÇÃO DE DNA DIRECIONADA POR sIRNA E RNA BRPI0806902A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88141807P 2007-01-19 2007-01-19
PCT/IB2008/000954 WO2008087561A2 (en) 2007-01-19 2008-01-18 Methods and compositions for modulating the sirna and rna-directed-dna methylation pathways

Publications (1)

Publication Number Publication Date
BRPI0806902A2 true BRPI0806902A2 (pt) 2014-06-17

Family

ID=39636444

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0806902-6A2A BRPI0806902A2 (pt) 2007-01-19 2008-01-18 MÉTODOS E COMPOSIÇÕES PARA MODULAÇÃO DAS VIAS DE METILAÇÃO DE DNA DIRECIONADA POR sIRNA E RNA

Country Status (6)

Country Link
US (1) US20100169996A1 (pt)
EP (1) EP2121939B1 (pt)
BR (1) BRPI0806902A2 (pt)
CA (1) CA2675946A1 (pt)
ES (1) ES2447840T3 (pt)
WO (1) WO2008087561A2 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288354B2 (en) 2005-12-28 2012-10-16 The Scripps Research Institute Natural antisense and non-coding RNA transcripts as drug targets
CN105420268A (zh) * 2006-12-21 2016-03-23 诺维信股份有限公司 通过移行rna干扰来降低或消除丝状真菌菌株中的基因表达的方法
MX339820B (es) 2008-10-03 2016-06-13 Curna Inc Compuestos oligonucleottidos designados para inhibir el transcrito antisentido natrual apra apolipoproteina-a1.
CN102317458B (zh) 2008-12-04 2018-01-02 库尔纳公司 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
KR101866152B1 (ko) 2008-12-04 2018-06-08 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
ES2600781T3 (es) 2008-12-04 2017-02-10 Curna, Inc. Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
EP3009150B1 (en) 2009-02-12 2019-11-13 CuRNA, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2010107733A2 (en) 2009-03-16 2010-09-23 Curna, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
WO2010107740A2 (en) 2009-03-17 2010-09-23 Curna, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
EP2427552B1 (en) 2009-05-06 2016-11-16 CuRNA, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
CN103223177B (zh) 2009-05-06 2016-08-10 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
EP2427554B1 (en) 2009-05-08 2016-11-16 CuRNA, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
EP2432881B1 (en) 2009-05-18 2017-11-15 CuRNA, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
US8895527B2 (en) 2009-05-22 2014-11-25 Curna, Inc. Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
JP5960049B2 (ja) 2009-05-28 2016-08-02 クルナ・インコーポレーテッド 抗ウイルス遺伝子に対する天然アンチセンス転写物の抑制による抗ウイルス遺伝子関連疾患の治療
CN102695797B (zh) 2009-06-16 2018-05-25 库尔纳公司 通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
US8951981B2 (en) 2009-06-16 2015-02-10 Curna, Inc. Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
CA2765889A1 (en) 2009-06-24 2010-12-29 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
CA2765815A1 (en) 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
KR101801407B1 (ko) 2009-07-24 2017-11-24 큐알엔에이, 인크. 시르투인 (ｓｉｒｔ)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
JP6128848B2 (ja) 2009-08-05 2017-05-17 クルナ・インコーポレーテッド インスリン遺伝子（ｉｎｓ）に対する天然アンチセンス転写物の抑制によるインスリン遺伝子（ｉｎｓ）関連疾患の治療
CA2770104C (en) 2009-08-11 2019-03-19 Opko Curna, Llc Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
WO2011022606A2 (en) 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
CN102482671B (zh) 2009-08-25 2017-12-01 库尔纳公司 通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
US20120295952A1 (en) 2009-09-25 2012-11-22 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
RU2639550C2 (ru) 2009-12-16 2017-12-21 Курна, Инк. Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1
CN102781480B (zh) 2009-12-23 2018-07-27 库尔纳公司 通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
US8940708B2 (en) 2009-12-23 2015-01-27 Curna, Inc. Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
JP5982288B2 (ja) 2009-12-29 2016-08-31 カッパーアールエヌエー，インコーポレイテッド 腫瘍タンパク質６３（ｐ６３）に対する天然アンチセンス転写物の阻害による腫瘍タンパク質６３関連疾患の治療
EP2519633B1 (en) 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
EP2519632B1 (en) 2009-12-31 2018-04-11 CuRNA, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
RU2611187C2 (ru) 2010-01-04 2017-02-21 Курна, Инк. Лечение заболеваний, связанных с интерферон-регуляторным фактором 8 (irf8), путем ингибирования природного антисмыслового транскрипта к irf8
EP2521785B1 (en) 2010-01-06 2022-03-09 CuRNA, Inc. Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases
KR101854926B1 (ko) 2010-01-11 2018-05-04 큐알엔에이, 인크. 성 호르몬 결합 글로불린 (ｓｈｂｇ)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (ｓｈｂｇ) 관련된 질환의 치료
CA2786568A1 (en) 2010-01-25 2011-07-28 Curna, Inc. Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
JP5976548B2 (ja) 2010-02-22 2016-08-23 カッパーアールエヌエー，インコーポレイテッド Ｐｙｃｒ１に対する天然アンチセンス転写物の阻害によるピロリン−５−カルボン酸レダクターゼ１（ｐｙｃｒ１）関連疾患の治療
CA2795145C (en) 2010-04-02 2019-01-22 Curna, Inc. Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
CN102858979B (zh) 2010-04-09 2018-01-26 库尔纳公司 通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
KR20130101442A (ko) 2010-05-03 2013-09-13 큐알엔에이, 인크. 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
EP2576784B1 (en) 2010-05-26 2017-11-15 CuRNA, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
DK2576783T3 (en) 2010-05-26 2018-03-12 Curna Inc TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
JP6023705B2 (ja) 2010-06-23 2016-11-09 カッパーアールエヌエー，インコーポレイテッド ナトリウムチャネル、電位依存性、αサブユニット（ＳＣＮＡ）に対する天然アンチセンス転写物の阻害によるＳＣＮＡ関連疾患の治療
EP2593547B1 (en) 2010-07-14 2017-11-15 CuRNA, Inc. Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
KR101886457B1 (ko) 2010-10-06 2018-08-07 큐알엔에이, 인크. 시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료
CN103180445B (zh) 2010-10-22 2018-02-16 库尔纳公司 通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
EP2640738A1 (en) * 2010-11-15 2013-09-25 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
CA2818824A1 (en) 2010-11-23 2012-05-31 Joseph Collard Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
RU2620980C2 (ru) 2011-06-09 2017-05-30 Курна, Инк. Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
JP6125505B2 (ja) 2011-09-06 2017-05-10 カッパーアールエヌエー，インコーポレイテッド 小分子による電位開口型ナトリウムチャネル・アルファサブユニット関連疾患の治療
TR201815503T4 (tr) 2012-03-15 2018-11-21 Curna Inc Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi.
WO2014028833A1 (en) * 2012-08-17 2014-02-20 Novozymes A/S Methods for co-silencing expression of genes in filamentous fungal strains and uses thereof
CN109554496A (zh) * 2018-12-17 2019-04-02 北京林业大学 一种检测胁迫处理前后植物中转座子活性变化的方法
EP4294933A4 (en) * 2021-02-19 2025-10-15 Nuclear Rna Networks Inc COMPOSITIONS AND METHODS FOR MODULATING GENE TRANSCRIPTION NETWORKS BASED ON SHARED HIGH-IDENTITY TRANSPOSABLE ELEMENT SEQUENCES AND NON-PROCESSIVE PROMOTER TRANSCRIPTS AND PROMOTER-PROXIMAL TRANSCRIPTS
US20250270583A1 (en) * 2022-10-26 2025-08-28 Biodrive, Inc. Methods for Suppression of Gene Silencing in Plants
CN116622739B (zh) * 2023-06-25 2023-11-28 中国农业科学院植物保护研究所 番茄SlSUVH2或SlSUVH4基因在调控双生病毒中的应用及转基因植物培育方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4031758A1 (de) 1990-10-06 1992-04-09 Bayer Ag Resistenz-gene
US5629470A (en) * 1995-01-20 1997-05-13 Rutgers, The State University Of New Jersey Transgenic plants and plant cells with enhanced pathogen resistance and related methods
GB0021879D0 (en) 2000-09-06 2000-10-18 Univ Edinburgh Plant resistance gene

Also Published As

Publication number Publication date
EP2121939A2 (en) 2009-11-25
WO2008087561A9 (en) 2009-10-15
CA2675946A1 (en) 2008-07-24
WO2008087561A8 (en) 2008-10-09
WO2008087561A2 (en) 2008-07-24
WO2008087561A3 (en) 2009-04-09
ES2447840T3 (es) 2014-03-13
US20100169996A1 (en) 2010-07-01
EP2121939B1 (en) 2013-12-04

Similar Documents

Publication Publication Date Title
BRPI0806902A2 (pt) MÉTODOS E COMPOSIÇÕES PARA MODULAÇÃO DAS VIAS DE METILAÇÃO DE DNA DIRECIONADA POR sIRNA E RNA
FR2929502B1 (fr) Implant nucleique.
DK2417257T3 (da) Tricyclo-dna-antisense-oligonukleotider, sammensætninger, og fremgangsmåder til behandlingen af sygdom
BRPI0815725A2 (pt) Métodos para detecção de oligonucleotídeos
DK2200646T3 (da) RNA-Vacciner
GB201014134D0 (en) Methods of RNA aplification in the presence of DNA
BRPI0812446A2 (pt) Métodos para aperfeiçoamento de propriedades de proteína múltiplas
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0716439A2 (pt) formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas.
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI0912046A2 (pt) composições de hibridização e métodos
BRPI0811170A2 (pt) Oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
BRPI0908876A2 (pt) barreiras para facilitação de reações biológicas
BRPI0919252A2 (pt) Métodos para cultivar células, propagação e purificação de vírus
BRPI0718796A2 (pt) Nucleotídeo
BRPI0909212A2 (pt) Composições e método para sequeciamento de ácido nucléico
BRPI0815841A2 (pt) Métodos e composições para melhoramento de traços preferidos.
BRPI0809573A2 (pt) composição, e, método
DK1984502T3 (da) Nukleinsyre
DE112009000578A5 (de) Reibahle
BRPI0822218A2 (pt) Transferases e oxidorredutases, ácidos nucleicos que as codificam e métodos para fazê-las e usá-las.
BRPI0921959A2 (pt) métodos e composições para remoção de tatuagem
BRPI0910763A2 (pt) métodos e dispositivos para dissecção de tecidos
BRPI0811786A2 (pt) Acionador para inalador dosimetrado
BRPI0814167A2 (pt) Composição, e, método

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.